<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03956264</url>
  </required_header>
  <id_info>
    <org_study_id>2019/01</org_study_id>
    <nct_id>NCT03956264</nct_id>
  </id_info>
  <brief_title>Interest of Virtual Reality in the Management of Anxiety and Pain Related to Post-cardiac Surgery Care</brief_title>
  <acronym>ARVACC</acronym>
  <official_title>Interest of Virtual Reality in the Management of Anxiety and Pain Related to Post-cardiac Surgery Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CMC Ambroise Paré</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CMC Ambroise Paré</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares Virtual Reality versus Nitrous oxide administration for the management of
      anxiety and pain related to post-cardiac surgery care, especially during removal of
      mediastinal drainage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After cardiac surgery, the mediastinal drains are usually removed the second postoperative
      day, in the absence of complications. This procedure, realized by nurses, is a source of
      anxiety and pain for patients.

      Nitrous oxide (Kalinox®) is commonly used to manage many situations of anxiety, including the
      removal of mediastinal drains, and has shown a greater effect than placebo in this
      indication.

      Virtual Reality (VR) is a recent technology that allows the representation of a pleasant
      environment in three dimensions with a complete immersion by a helmet. By distracting
      patients, this technology can reduce anxiety, discomfort and ultimately pain associated with
      care.

      This randomized monocentric trial compares VR versus Kalinox® administration for the
      management of anxiety and pain related to post-cardiac surgery care, especially mediastinal
      drain removal.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 26, 2019</start_date>
  <completion_date type="Anticipated">September 26, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 26, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of patient comfort</measure>
    <time_frame>30 minutes</time_frame>
    <description>Variation of the Analgesia / Nociception Index (ANI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of pain during drain removal</measure>
    <time_frame>30 minutes</time_frame>
    <description>Pain VRS ranging from 0 to 10 (0=no pain, 10=worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of anxiety during drain removal</measure>
    <time_frame>30 minutes</time_frame>
    <description>Anxiety VRS ranging from 0 to 10 (0=no stress, 10=worst possible stress)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphine consumption</measure>
    <time_frame>1 hour</time_frame>
    <description>Cumulated dose of oxynorm (mg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects due to Virtual Reality</measure>
    <time_frame>2 hours</time_frame>
    <description>Onset of vertigo, nausea or vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>2 hours</time_frame>
    <description>Satisfaction VRS ranging from 0 to 4 (0=unsatisfied, 4=very satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health staff satisfaction</measure>
    <time_frame>30 minutes</time_frame>
    <description>Satisfaction VRS ranging from 0 to 4 (0=unsatisfied, 4=very satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects due to Kalinox</measure>
    <time_frame>2 hours</time_frame>
    <description>Onset of delirium, euphoria or headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between ANI and Pain VRS</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between ANI and Anxiety VRS</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Surgery, Cardiac</condition>
  <arm_group>
    <arm_group_label>VR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VR Installation 5 min before the drain removal and stop 10 min after the procedure.
If Pain assessed by verbal rating scale (VRS) &gt; 4, administration of morphine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kalinox®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Start of Kalinox® administration by inhalation with a facial mask 1 min before the drain removal and stop after the procedure according to the usual procedure of the service.
If Pain VRS &gt; 4, administration of morphine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Virtual Reality</intervention_name>
    <description>Deepsen offers a VR platform that provides patients with immersive contents aimed to distract, inform, soften and improve the healthcare experience</description>
    <arm_group_label>VR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kalinox</intervention_name>
    <description>Gas mixture composed of 50% Nitrous Oxide and 50% Oxygen</description>
    <arm_group_label>Kalinox®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Extubated after cardiac surgery

          -  Sinus rhythm

          -  Consent for participation

          -  Affiliation to the social security system

        Exclusion Criteria:

          -  Pacemaker

          -  Visual acuity making impossible the use of virtual reality

          -  Intolerance to morphine

          -  Contraindication to Kalinox®

          -  Pregnant or breastfeeding women

          -  Patients under protection of the adults (guardianship, curators or safeguard of
             justice)

          -  Communication difficulties or neuropsychiatric disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierre Squara, MD</last_name>
    <phone>0146418971</phone>
    <email>pierre.squara@orange.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CMC Ambroise Paré</name>
      <address>
        <city>Neuilly-sur-Seine</city>
        <state>Ile-de-France</state>
        <zip>92200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Driss Laghlam, MD</last_name>
      <phone>0146418971</phone>
      <email>driss.laghlam@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Driss Laghlam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Mediastinal drain removal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

